Organization (Other)
Janssen (France)
ClinicalTrials.gov lists Janssen (France) as lead sponsor of 1,100 trials, counting the companies grouped under it. Janssen (France) itself has 867 active development programs and 230 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. Companies grouped under this one are not included. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 35 registered with a 2026 start date. The hollow diamonds on the dashed line are a forecast of the full-year count, planned starts included: about 44 in 2026 and about 38 in 2027, the average of the 24 months through September, counted as registered and carried forward. The columns, the lighter one included, count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. This method has not been backtested on organizations. In backtests on conditions with as many trial starts a year as this organization (20 to 100), forecasts made part-way through the year were typically off by about 18 percent and ran about 14 percent low against the count later registered; forecasts made before the year began were off by about 26 percent and ran about 20 percent low against the count later registered. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored. 2 trials are registered to start in 2027 or later.
Logo Johnson & Johnson Services, Inc., via Wikimedia Commons, Public domain. Shown to identify the organization; it may be a registered trademark.
This page covers Janssen (France) and 1 company grouped under it: 1,100 lead-sponsored trials (1,100 its own, 0 in the grouped companies) and 15 legal-entity registrations (14 its own, 1 in the grouped companies).
Related companies are recorded in the same corporate group by GLEIF, ROR or a curator but are not grouped here; they are listed below with their own counts and are not included in the figures above.
Companies grouped under this page (1)
| Company | Lead trials | Legal entities |
|---|---|---|
| Cilag (Switzerland) | 0 | 1 |
Disease areas (241)
Shown in this order: most trials first (counted at this company's own legal-entity record, not the consolidated group).
| Disease area | Trials |
|---|---|
| Multiple Myeloma | 81 |
| Prostatic Neoplasms | 53 |
| Inflammatory Bowel Diseases | 45 |
| Lymphoma | 44 |
| Lymphoma, Non-Hodgkin | 39 |
Showing 5 of 241 disease areas.
Trials by start year as sponsor or collaborator (23)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 2 trials are registered to start in 2027 or later, and not listed here.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 35 |
| 2025 | 30 |
| 2024 | 36 |
| 2023 | 39 |
| 2022 | 61 |
| 2021 | 81 |
| 2020 | 63 |
| 2019 | 70 |
| 2018 | 74 |
| 2017 | 76 |
Showing 10 of 23 years.
Prediction, not a registry value: median of 36 months from start to primary completion across 90 trials still running at the 2026-10-09 snapshot; registered median of 15 months across 767 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (867)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| Amivantamab | Lung Neoplasms | Phase 3 | 14 |
| Amivantamab | Carcinoma, Non-Small-Cell Lung | Phase 3 | 14 |
| DARATUMUMAB | Multiple Myeloma | Phase 3 | 26 |
| DEXAMETHASONE | Multiple Myeloma | Phase 3 | 24 |
| Teclistamab | Multiple Myeloma | Phase 3 | 13 |
Showing 5 of 867 active programs.
Approved assets (230)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| Guselkumab | 36 |
| IBRUTINIB | 29 |
| Ustekinumab | 18 |
| METFORMIN | 15 |
| Canagliflozin (JNJ-28431754) 100 mg | 13 |
Showing 5 of 230 approved assets.
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 59% hit target (n=416) | 43% on time (n=389) |
Biomarker capability evidence (2,101)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| AARS1 | Trial sponsor | Named in trial inclusion criteria |
| AARS2 | Trial sponsor | Named in trial inclusion criteria |
| ABCD2 | Trial sponsor | Named in trial inclusion criteria |
| ACD | Trial sponsor | Primary endpoint in a Phase 3 trial |
| ACE | Trial sponsor | Named in trial inclusion criteria |
Showing 5 of 2,101 evidence rows.
Not on this page
Checked, with nothing recorded for this organization: sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, organization relationships, and clia clinical laboratory certificates.
Counted at group level under Johnson & Johnson: journals published in, us granted patents, latest dated events, and biomarkers this organization publishes on.